BioCurate has announced a new agreement with leading Australian commercialisation fund Uniseed to collaborate on projects of specific interest and facilitate commercialisation of intellectual property at the University of Melbourne.
BioCurate is an independently-operated joint venture between the University of Melbourne and Monash University. It was established in 2016 with the support of the Victorian State Government. It is focussed on translating and commercialising early-stage medical research to bring new medicines to patients.
Uniseed, which is now in its twentieth year of operation, is Australia’s longest-running early-stage commercialisation fund that makes investments in research emanating from five of Australia’s leading research organisations – The University of Queensland, The University of Sydney, UNSW Sydney, The University of Melbourne and the CSIRO.
The new agreement will provide both parties with potential co-investment opportunities in early-stage research into new drugs and therapeutics.
According to Peter Devine, CEO of Uniseed, “We are excited to enter this collaboration with BioCurate, as it will ensure early stage drug and therapeutic projects are appropriately funded and managed, and given the best chance of success through the collective input and experience of the Uniseed and BioCurate teams."
Dr Glenn Begley, CEO of BioCurate, said the organisation had been in discussions with Uniseed to explore ways both entities can work together to commercialise early-stage research.
“We are delighted to be joining forces with Uniseed in our mission to bring critical new medicines to patients and help realise the potential of Australia’s biomedical research community. The Uniseed team bring invaluable industry experience that will be instrumental in our continued efforts to accelerate the development of new drugs that have the greatest commercial potential,” Dr Begley said.